[Progress in developing anti-Alzheimer drugs].
According to the amyloid hypothesis, accumulation of beta amyloid in the brain seems to be the primary influence driving Alzheimer's disease pathogenesis. From the studies of A beta production, aggregation, degradation and clearance, several strategies for preventing or delaying the disease onset and progression have been postulated. These are beta-secretase inhibitors, gamma-secretase inhibitors, A beta degrading enzymes, anti-cholesterol drugs, non-steroidal anti-inflammatory drugs, beta-sheet breakers, chelating agents, SAP competitors, beta-amyloid vaccination, agents for trapping peripheral A beta, and so on. Here I review recent progress in developing anti-Alzheimer drugs.
Tabira
Takeshi
T
National Institute for Longevity Sciences, Obu, Aichi 474-8522, Japan.
D000544:Alzheimer Disease / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D023582:Alzheimer Vaccines / Q000627:therapeutic use; D053829:Amyloid Precursor Protein Secretases; D016229:Amyloid beta-Peptides / Q000276:immunology / Q000378:metabolism; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D016282:Aspartic Acid Endopeptidases; D001921:Brain / Q000378:metabolism; D015195:Drug Design; D010450:Endopeptidases; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans
D023582:Alzheimer Vaccines; D016229:Amyloid beta-Peptides; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000924:Anticholesteremic Agents; D004791:Enzyme Inhibitors; D053829:Amyloid Precursor Protein Secretases; D010450:Endopeptidases; D016282:Aspartic Acid Endopeptidases; C509280:BACE1 protein, human